Evidence map›Paper›PMID 40594543›Full record

ArticleScientific reports2025

Cold atmospheric plasma effectively kills chordoma cells through induction of intracellular reactive oxygen species.

Sophie Peeters, Peter B Wu, Blake Haist, Amber Armellini, Wi Jin Kim, Zhitong Chen, Richard Obenchain, George Ayad, Weihong Ge, Aparna Bhaduri and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sophie PeetersDepartment of Neurosurgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. Sophie.Peeters0@gmail.com.
Peter B WuDepartment of Neurosurgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Blake HaistDepartment of Mechanical and Aerospace Engineering, University of California Los Angeles, Los Angeles, CA, USA.
Amber ArmelliniDepartment of Neurosurgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Wi Jin KimDepartment of Neurosurgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Zhitong ChenDepartment of Mechanical and Aerospace Engineering, University of California Los Angeles, Los Angeles, CA, USA.
Richard ObenchainDepartment of Mechanical and Aerospace Engineering, University of California Los Angeles, Los Angeles, CA, USA.
George AyadDepartment of Neurosurgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Weihong GeDepartment of Biological Chemistry, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Aparna BhaduriDepartment of Neurosurgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Graeme SabistonDepartment of Mechanical and Aerospace Engineering, University of California Los Angeles, Los Angeles, CA, USA.
Robert M PrinsDepartment of Neurosurgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Richard WirzDepartment of Mechanical and Aerospace Engineering, University of California Los Angeles, Los Angeles, CA, USA.
Anthony C WangDepartment of Neurosurgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. ACWang@mednet.ucla.edu.

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
UCLA Tumor Immunology Training ProgramT32CA009120 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Steven M. Dubinett, MICHAEL A TEITELL · 1985 to 2026
$10.3M
UCLA Neurosurgery Research Training and Education ProgramR25NS079198 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LIAU, LINDA M · 2012 to 2021
$1.2M
NCI NIH HHS P50 CA211015NCI NIH HHS T32 CA009120NINDS NIH HHS R25 NS079198
6 · The paper itself

Abstract

Chordomas remain one of the most difficult-to-treat of skull base tumors. The best chance of survival and cure to date is with en bloc radical surgical resection, followed by adjuvant radiotherapy. Oftentimes, tumor infiltration into functionally critical, or difficult-to-access areas, precludes optimal resection. The median overall survival for these tumors is 116 months. Cold atmospheric plasma (CAP) is generated by applying a high voltage electric field to helium or argon feed gases, resulting in reactive atmospheric species. Over the past decade, CAP has been applied experimentally in a number of oncologic conditions and has demonstrated anti-tumor effects both in vitro and in vivo. Additionally, CAP has been shown to increase cancer cells' sensitivity to radiation and could therefore be a useful tool in improving chordoma recurrence rates as an intraoperative adjuvant therapy to the current standard of care. To date, there are no studies in the literature examining the efficacy of CAP in inducing cytotoxicity in chordoma. We treated CH2, CH7 and UM-Chor1 chordoma cells with CAP, measuring resulting cell viability and intracellular ROS accumulation. Here, we show a dose-dependent increase in intracellular ROS and cell death with direct CAP exposure in vitro, finding an exquisite sensitivity of chordoma cells to CAP-mediated cytotoxicity.

Indexed as

ChordomaPlasma GasesReactive Oxygen SpeciesArgonCell Line, TumorCell SurvivalHumansArgonPlasma GasesReactive Oxygen SpeciesChordomaCold atmospheric plasmaReactive oxygen species

Identifiers

PMID40594543
PMCPMC12219751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.